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Abstract
Background: nab-Paclitaxel is an albumin-bound formulation of paclitaxel approved for the treatment of metastatic
breast cancer (MBC). This analysis was designed to characterize the treatment patterns, efficacy, and safety of
nab-paclitaxel for MBC treatment using health claims data from US health plans associated with Optum.
Methods: Women aged ≥ 18 years who initiated nab-paclitaxel for MBC treatment from January 1, 2005, to
September 30, 2012, and who met eligibility criteria were selected from the Optum Research Database for
this analysis. Patients were required to have complete medical coverage and pharmacy benefits, ≥ 6 months
of continuous enrollment, and a diagnosis of MBC prior to nab-paclitaxel initiation. The pattern of use for
nab-paclitaxel (eg, regimen, schedule, duration, and administration) and claims-captured toxicities were
characterized by line of therapy. Overall survival (OS) and time to next therapy or death (TNTD) were
described by line of therapy, regimen, and schedule.
Results: Of the 664 nab-paclitaxel patients, 172 (25.9 %) received it as first-line therapy, 211 (31.8 %) as
second-line therapy, and 281 (42.3 %) as third-line or later therapy. Overall, the majority of patients received
monotherapy (61 %) and followed a weekly (71 %) rather than an every 3 weeks treatment schedule. nab-Paclitaxel
was often (31.7 %) combined with targeted therapy (57.5 % with bevacizumab and 23.9 % with trastuzumab
or lapatinib). The median duration of therapy was 128 days (4.2 months). For the overall population, median
OS was 17.4 months (22.7, 17.4, and 15.1 months in first-, second-, and third-line or later therapy, respectively). Median
TNTD was 6.1 months (7.1, 6.6, and 5.3 months in first-, second-, and third-line or later therapy, respectively).
For patients aged ≤ 50 years or with ≥ 3 metastatic sites, median OS was 15.6 months. No new safety signal
was identified.
Conclusions: In this US healthcare system, the majority of patients received nab-paclitaxel as second-line
or later therapy, monotherapy, and weekly treatment. The efficacy and safety outcomes of nab-paclitaxel
observed in this real-world setting appear consistent with those from clinical trial data.
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Background
Taxanes are some of the most active chemotherapeutic
agents in the treatment of breast cancer [1–3]. However,
sensory neuropathy, neutropenia, and significant toxici-
ties—such as severe hypersensitivity reactions, which
require substantial premedication with high doses of ste-
roids and antihistamines—have been reported in patients
treated with solvent-based (sb) taxanes (ie, paclitaxel and
docetaxel) [4–6]. An albumin-bound formulation of pacli-
taxel (Abraxane®, nab-paclitaxel) was developed in an
effort to overcome the toxicities associated with sb-
paclitaxel and improve efficacy [7]. Preclinical studies have
shown that nab-paclitaxel delivers a 33 % higher paclitaxel
concentration to tumors and demonstrates enhanced
transport across endothelial cell monolayers compared
with sb-paclitaxel [7]. Recently published population phar-
macokinetic data on nab-paclitaxel compared with sb-
paclitaxel demonstrated more rapid and greater tissue
penetration and slower elimination of paclitaxel [8]. nab-
Paclitaxel was approved by the US Food and Drug Admin-
istration in January 2005 for the treatment of breast
cancer after failure of combination chemotherapy, includ-
ing anthracyclines, for metastatic disease or relapse within
6 months of adjuvant chemotherapy [9].
The safety and efficacy of single-agent nab-paclitaxel
have been well established in clinical trials of patients
with metastatic breast cancer (MBC) (Table 1) [10–13].
In a phase three trial [10], nab-paclitaxel dosed at
260 mg/m2 every 3 weeks (q3w) vs sb-paclitaxel dosed
at 175 mg/m2 q3w demonstrated a significantly higher
overall response rate (33 % vs 19 %; P = 0.001) and a
significantly longer time to tumor progression (5.3 vs
3.9 months; P = 0.006). The incidence of grade 4 neu-
tropenia was significantly lower with nab-paclitaxel
compared with sb-paclitaxel. Although the incidence of
grade 3 sensory neuropathy was significantly higher
with nab-paclitaxel compared with sb-paclitaxel, it was
manageable with dose modifications and treatment in-
terruptions and improved to grade ≤ 2 in a median of
22 days. Although the 260 mg/m2 q3w nab-paclitaxel
monotherapy regimen is indicated for the treatment of
patients with MBC, other doses and schedules of nab-
paclitaxel have been explored in clinical trials. In a
phase two trial, three different nab-paclitaxel regimens
(300 mg/m2 q3w, 100 mg/m2, or 150 mg/m2 given
weekly for the first 3 of 4 weeks [qw 3/4]) were com-
pared with docetaxel 100 mg/m2 q3w for the treatment
of chemotherapy-naive patients with MBC [12, 13]. Re-
sults from this trial indicated that the 150 mg/m2 qw 3/
4 dose of nab-paclitaxel was a significantly more effect-
ive regimen than docetaxel [13]. Median overall
survival (OS) was 33.8 months compared with 22.2,
27.7, and 26.6 months for nab-paclitaxel 100 mg/m2 qw
3/4, nab-paclitaxel 300 mg/m2 q3w, and docetaxel,
respectively [13]. The frequency of grade 3/4 neutro-
penia, febrile neutropenia, and fatigue was lower in all
nab-paclitaxel arms compared with docetaxel. The inci-
dence of grade 3 sensory neuropathy was higher for the
300 mg/m2 q3w and 150 mg/m2 qw 3/4 nab-paclitaxel
regimens vs docetaxel, which may be related to the
higher median dose intensities associated with these
two nab-paclitaxel dose regimens (100 and 101 mg/m2/
week, respectively), compared with docetaxel (33 mg/m2/
week) [13]. The median time to improvement of sensory
neuropathy to ≤ grade 2 was 20 to 22 days for nab-pacli-
taxel compared with 41 days for docetaxel [13].
nab-Paclitaxel has also been studied in combination
with other cytotoxic or targeted agents for the treatment
of MBC (Table 1) [14–19]. Results of phase two trials of
nab-paclitaxel in combination with gemcitabine and oral
capecitabine have demonstrated efficacy and favorable
tolerability. The results of other clinical trials have
shown that nab-paclitaxel is a reasonable substitution
for sb-taxanes in combination with targeted agents such
as bevacizumab, trastuzumab, and lapatinib for the treat-
ment of MBC [16–21].
Clinical trials target highly selected patients with re-
strictive eligibility criteria, limiting the generalizability of
outcomes. Therefore, we conducted an observational
study based on US health insurance claims data to
characterize the therapeutic context (line of therapy,
monotherapy vs combination therapy, and dosing sched-
ule) and to estimate the OS and time to next therapy or
death (TNTD) among patients who received nab-pacli-
taxel for the treatment of MBC.
Methods
Data source
In this retrospective cohort study, health insurance
claims data were extracted from the Optum Research
Database, which contains eligibility, pharmacy claims,
medical claims, and other information, such as mortality
data, from health plans associated with Optum. The
health claims are linked to enrollment information with
data covering the period from 1993 to present. The in-
formation in the claims database includes over 12 mil-
lion individuals from geographically diverse locations
across the United States who have both medical and
pharmacy benefit coverage. Medical claims or encounter
data were collected from all available healthcare sites
(inpatient hospital, outpatient hospital, emergency room,
physician’s office, surgery center, etc.) for virtually all
types of provided services, including specialty, prevent-
ive, and office-based treatments. Diagnoses on the
claims are recorded using International Classification of
Disease, Ninth Revision Clinical Modification (ICD-9-CM)
codes. Procedures map to ICD-9-CM, Current Proced-
ural Terminology, and Healthcare Common Procedure
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Coding System codes. Pharmacy claims data include
drug name, dosage form, drug strength, fill date, days of
supply, financial information, and de-identified patient
and prescriber codes, allowing for longitudinal tracking
of medication refill patterns and changes in medications.
Study population
The study population consisted of women aged ≥ 18 years
with a diagnosis of MBC who received nab-paclitaxel
treatment. Patients were eligible for the study if they had
complete medical coverage and pharmacy benefits;
had ≥ 6 months of continuous enrollment in a US health
plan from January 1, 2005 to September 30, 2012; and had
a diagnosis of MBC prior to the initiation of nab-pacli-
taxel. Patients were selected for the claims analysis based
on the criteria listed in Fig. 1. Diagnosis codes appearing
on claims suggesting a laboratory or diagnostic service
were not considered when these criteria were applied, be-
cause these claims often reflect a “rule-out” diagnosis that
has not yet been confirmed.
Table 1 Select clinical trials of nab-P in metastatic breast cancer
Trial Phase Patient population Regimen Efficacy Selecta Grade≥ 3 AEs, %
PFS, mo OS, mo Neutropenia Neuropathy
Monotherapy
Ibrahim et al. 2005 [11] 2 First line
(n = 15)
nab-P 300 mg/m2 q3w TTP 6.1 14.6 51 11b
Second line or later
(n = 48)
Gradishar et al. 2009 [12]
& 2012 [13]
2 First line nab-P 300 mg/m2 q3w (n = 76) 11.0 27.7 43 21b
nab-P 100 mg/m2 qw 3/4 (n = 76) 12.8 22.2 25 9b
nab-P 150 mg/m2 qw 3/4 (n = 74) 12.9 33.8 45 22b
Gradishar et al. 2005 [10] 3 First line
(n = 97)
nab-P 260 mg/m2 q3w TTP 5.3 15.0 30 10b
Second line or later
(n = 132)
Combination therapy with cytotoxic agents
Roy et al. 2009 [14] 2 First line
(N = 50)
nab-P 125 mg/m2 + gemcitabine









nab-P 125 mg/m2 qw 2/3 + oral
capecitabine 825 mg/m2 twice
daily on days 1 and 15 of a
21-day cycle
10.6 19.9 10 2b
HER2 negative
Combination therapy with targeted agents
Seidman et al. 2013 [16] 2 First line, HER2
negative
nab-P 130 mg/m2 qw + bev
10 mg/kg q2w (n = 79)
8.8 23.7 33 46
nab-P 260 mg/m2 q2w + bev
10 mg/kg q2w (n = 54)
5.8 19.0 6 56
nab-P 260 mg/m2 q3w + bev
15 mg/kg q3w (n = 75)
7.7 21.3 16 33
Rugo et al. 2015 [17] 3 First line,
predominantly
HER2 negative
nab-P 150 mg/m2 qw 3/4 + bev
10 mg/kg q2w (n = 271)
9.3 23.5 51 27




nab-P 125 mg/m2 qw 3/4 + trastuzumab
4 mg/kg bolus then 2 mg/kg qw
(HER2 positive only)
14.5 29.0 11b 8b
HER2 positive
(n = 22)
Yardley et al. 2013 [19] 2 First/second
line (N = 60)
nab-P 125 mg/m2 qw 3/4 + oral




AE adverse event, bev bevacizumab, HER2 human epidermal growth factor receptor, nab-P nab-paclitaxel, OS overall survival, PFS progression-free survival,
TTP time to tumor progression, qw every week, q2w every 2 weeks, q3w every 3 weeks, qw 2/3 weekly for the first 2 of 3 weeks; qw 3/4 weekly for the first 3
of 4 weeks
aNeutropenia and neuropathy are common grade ≥ 3 toxicities associated with nab-P treatment
bNo grade 4 events
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Lines of therapy
New users of nab-paclitaxel were defined as those
with a first dispensing of nab-paclitaxel within the
study period (January 1, 2005 to September 30,
2012), with no dispensing of nab-paclitaxel during
the 6 months prior to the first dispensing (baseline
period). Patients who received neoadjuvant (≤4 months
prior to surgery) or adjuvant (≤90 days after surgery)
therapy with nab-paclitaxel were excluded. The index
date was defined as the date of nab-paclitaxel initiation.
Patients who met the cohort entry eligibility criteria
were further categorized into 3 subgroups by line of
therapy (first-, second-, or third-line or later) with nab-
paclitaxel.
A patient must have received ≥ 1 cycle (defined as
30 days) of treatment prior to being defined as
switching to a greater line of therapy. Any switching
or addition of agents within 30 days of the start of
each line of therapy was considered to be the same
line of therapy.
First-line therapy
First-line therapy with nab-paclitaxel was defined as ini-
tial dispensing of nab-paclitaxel as the first chemother-
apy received after a diagnosis of metastatic disease. All
agents received within 30 days following nab-paclitaxel
were considered part of first-line therapy.
Second-line therapy
Second-line therapy with nab-paclitaxel was defined as
dispensing of nab-paclitaxel as part of second-line ther-
apy, defined as additional treatment different from the
first-line therapy and initiated ≥ 30 days after the first
chemotherapy or after a large gap (eg, 90 days) in therapy.
Third-line or later therapy
Third-line or later therapy with nab-paclitaxel was de-
fined as a first dispensing of nab-paclitaxel as part of
third-line therapy, defined as any additional treatment
different from any initiated first- or second-line therapy
and after 60 days of the first chemotherapy or after a
large gap (eg, 90 days) in therapy. Similar methods were
used to identify later lines of therapy.
Outcome identification
The study outcomes included all-cause death, TNTD,
and major toxicities following nab-paclitaxel initiation.
All-cause death was identified using Social Security Ad-
ministration data linked to claims data. TNTD was used
as a surrogate of progression-free survival (PFS). Major
toxicities were identified following each line of therapy
and determined by tabulating the 25 most frequent ICD-
9-CM diagnoses codes. The toxicities of interest in-
cluded select adverse events consistent with the known
safety profile of nab-paclitaxel: neutropenia, anemia,
thrombocytopenia, infections, peripheral neuropathy,
Fig. 1 Flowchart of study patients. Patients in the Optum Research Database who met the criteria outlined in the flowchart were included in the
claims analysis. axx indicates any subcode
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asthenia, nausea, vomiting, diarrhea, fluid retention, my-
algia/arthralgia, and alopecia.
Statistical analysis
A descriptive analysis was conducted to identify the
background characteristics, nab-paclitaxel treatment
patterns, and nab-paclitaxel toxicities of interest in pa-
tients with MBC by line of therapy. The background
characteristics, including demographics and breast can-
cer risk factors, were ascertained during the 6-month
baseline period. Treatment patterns of nab-paclitaxel
were described in terms of treatment regimen (mono-
therapy or combination therapy), treatment schedule
(weekly or q3w), duration of line of therapy, number of
administrations, intervals between dispensings, and dose.
The occurrence of toxicity claims of interest following
nab-paclitaxel treatment was also summarized.
A survival analysis using an intent-to-treat approach
was performed to evaluate the OS and TNTD. Each pa-
tient was followed from nab-paclitaxel initiation in each
line of therapy until the first occurrence of a study end-
point (all-cause death and TNTD, separately), disenroll-
ment from the health plan (eg, a gap of > 32 days in
membership), or the end of the study period (September
30, 2012). OS was defined as the interval between the
first dispensing of nab-paclitaxel and death. TNTD was
defined as the interval between the first dispensing of
nab-paclitaxel and switching of line of therapy or death.
Kaplan-Meier plots were used to depict the cumulative
probability of OS and TNTD by line of therapy. The me-
dian OS and median TNTD as well as their 95 % CIs
were also estimated. These survival analyses were con-
ducted overall, by line of therapy, by regimen, and by
schedule. A subgroup analysis was also performed




There were 2637 nab-paclitaxel initiators identified dur-
ing the study period. After the eligibility criteria were ap-
plied, a total of 664 patients remained in the final
analysis (Fig. 1). The 664 eligible patients were predom-
inantly aged 50 to 69 years and were from the southern
region of the United States (Table 2). There were sparse
data recorded in the claims for family history of breast
cancer, oral contraceptive use, hormone replacement
therapy, alcohol use, obesity, and smoking. All patients
had physician visits during the 6-month baseline period,
38.3 % of patients visited an emergency department, and
31.8 % of patients were admitted to a hospital. The me-
dian duration of hospitalization was 5 days (Table 2).
The median length of health plan membership was
2.4 years prior to initiation of nab-paclitaxel.
nab-Paclitaxel treatment patterns
Treatment patterns by line of therapy are summarized in
Table 3. There were 172 (25.9 %) patients who received
nab-paclitaxel as first-line therapy, 211 (31.8 %) as
second-line therapy, and 281 (42.3 %) as third-line or
later therapy. Overall, there were 405 (61.0 %) users who
had nab-paclitaxel administered as monotherapy and
259 (39.0 %) who had nab-paclitaxel administered as
combination therapy. When nab-paclitaxel was given as
a combination therapy, targeted agents were often used
(57.5 % bevacizumab and 23.9 % trastuzumab or lapati-
nib). Bevacizumab combination was more often pre-
scribed in first-line therapy with nab-paclitaxel vs
trastuzumab or lapatinib (81.0 vs 4.8 %). Trastuzumab
combination therapy was more often given in the third
line or later (39.5 %) compared with first-line (4.8 %) or
second-line (17.1 %) therapy. Of the 605 users whose
treatment schedules could be determined, a majority
(n = 428 [70.7 %]) received weekly treatment and 177
(29.3 %) received q3w treatment. The median durations
that patients received nab-paclitaxel as first-line, second-
line, and third-line or later therapy were 159 days
(5.2 months), 119 days (3.9 months), and 122 days
(4.0 months), respectively (Table 3).
nab-Paclitaxel safety outcomes
Table 4 shows the claims of the major toxicities of inter-
est among patients without corresponding events during
the baseline period. Anemia (26.3 %), nausea and vomit-
ing (24.5 %), neutropenia (17.5 %), and asthenia (15.6 %)
were the most common incident claims. This study also
found that 14.5 % of claims were for peripheral neur-
opathy. These events were more frequently recorded in
patients with first-line therapy compared with patients
receiving nab-paclitaxel in later lines of therapy.
nab-Paclitaxel efficacy outcomes
Patients who received first-line nab-paclitaxel–based
therapy appeared to have longer median survival vs sec-
ond- and third-line or later therapy (Fig. 2): 22.7, 17.4,
and 15.1 months, respectively (Table 5; Fig. 2). Median
TNTD values were 7.1, 6.6, and 5.3 months by first-,
second-, and third-line or later therapy, respectively
(Table 5; Fig. 3). In the subgroup of patients aged ≤ 50 years
or who had ≥ 3 metastases (n = 400), the median OS
was 15.6 months (95 % CI, 12.9–17.4 months), and
the median TNTD was 5.7 months (95 % CI, 4.9–
6.4 months). Patients who received nab-paclitaxel
combination therapy had a median survival time of
18.7 months compared with 16.8 months for those
who received nab-paclitaxel monotherapy (Table 5);
the respective values for median TNTD were 6.5 and
5.8 months.
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Median OS and TNTD values stratified by line of therapy
and treatment schedule are shown in Table 6. Median OS
was 18.6 months for weekly and 17.4 months for q3w nab-
paclitaxel, and median TNTD was 6.5 months for weekly
and 6.0 months for q3w nab-paclitaxel, respectively.
Discussion
Breast cancer is a heterogeneous disease with various
clinical and biological features [22]. Multiple molecular
alterations and cellular pathway dysregulations may
occur during disease development and progression [23].
Some types of breast cancers are more aggressive than
others, and sensitivity to treatment may differ [24, 25].
To get a real-world look at nab-paclitaxel treatment pat-
terns, efficacy, and safety since market approval, we car-
ried out a claims-based retrospective analysis using a
large US commercial health insurance database and se-
lected women undergoing treatment with nab-paclitaxel
for MBC.
Consistent with the National Comprehensive Cancer
Network guidelines [1], our analysis indicated that nab-
paclitaxel was most often prescribed as second-line or
later therapy and administered as monotherapy. When
nab-paclitaxel was used in combination, the targeted
agents (e.g., bevacizumab, trastuzumab, or lapatinib)
were most often prescribed. Patients treated with nab-
paclitaxel in the first line appeared to have favorable sur-
vival relative to patients treated in later lines of therapy.
However, the treatment effect of nab-paclitaxel as first-
line therapy may have been overestimated because the cri-
teria for first-line therapy required patients to be treated
for at least 30 days. Therefore, patients who discontinued
Table 2 Baseline characteristics of nab-paclitaxel initiators by line of therapya
Characteristic First line (n = 172) Second line (n = 211) Third line or later (n = 281) All (N = 664)
n % n % n % n %
Age
≤ 39 y 4 2.3 7 3.3 16 5.7 27 4.1
40–49 y 36 20.9 53 25.1 64 22.8 153 23.0
50–59 y 53 30.8 78 37.0 116 41.3 247 37.2
60–69 y 58 33.7 60 28.4 66 23.5 184 27.7
≥ 70 y 21 12.2 13 6.2 19 6.8 53 8.0
Geographic area
Midwest 39 22.7 47 22.3 65 23.1 151 22.7
Northeast 12 7.0 11 5.2 25 8.9 48 7.2
South 91 52.9 123 58.3 146 52.0 360 54.2
West 30 17.4 30 14.2 45 16.0 105 15.8
Healthcare utilization
No. of physician visits
0 0 0 0 0 0 0 0 0
1–2 2 1.2 2 0.9 3 1.1 7 1.1
≥ 3 170 98.8 209 99.1 278 98.9 657 98.9
No. of emergency department visits
0 103 59.9 117 55.5 190 67.6 410 61.7
1–2 51 29.7 82 38.9 72 25.6 205 30.9
≥ 3 18 10.5 12 5.7 19 6.8 49 7.4
No. of hospitalizations
0 119 69.2 138 65.4 196 69.8 453 68.2
1–2 47 27.3 68 32.2 77 27.4 192 28.9
≥ 3 6 3.5 5 2.4 8 2.8 19 2.9
Median IQR Median IQR Median IQR Median IQR
Length of health plan membership, y 2.6 (1.4–4.2) 1.9 (1.0–3.0) 2.7 (1.7–4.0) 2.4 (1.4–3.7)
Length of inpatient stay, db 5.0 (3.0–13.0) 4.0 (2.0–9.0) 5.0 (2.0–8.0) 5.0 (2.0–9.0)
IQR interquartile range
aData are from the Optum Research Database, January 1, 2005 to September 30, 2012
bAmong those with ≥ 1 hospital stay
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treatment early may not have been captured. Overall, the
safety and efficacy profiles of nab-paclitaxel in this setting
of US women with MBC were consistent with clinical trial
experience (Table 1) [10–19].
Our analysis showed a median OS of 17.4 months for
the overall population of patients with MBC who received
various doses, schedules, and regimens of nab-paclitaxel
across all lines of therapy. These results are in line with
those of a phase two trial [11] and the pivotal phase
three trial [10], which showed a median OS of 14.6 and
15.0 months, respectively, in patients receiving nab-
paclitaxel monotherapy (260–300 mg/m2 q3w) for ≥
first-line treatment of MBC (Table 1). In a phase two
trial of chemotherapy-naive patients with MBC, median
Table 4 Select adverse events among nab-paclitaxel initiators by line of therapy during the follow-up perioda,b
Adverse event First line (n = 172) Second line (n = 211) Third or later line (n = 281) All (N = 664)
Total nc n % Total nc n % Total nc n % Total nc n %
Neutropenia 165 33 20.0 190 26 13.7 222 42 18.9 577 101 17.5
Anemia 123 39 31.7 133 31 23.3 147 36 24.5 403 106 26.3
Thrombocytopenia 163 4 2.5 199 11 5.5 264 9 3.4 626 24 3.8
Infections 152 32 21.1 184 25 13.6 242 27 11.2 578 84 14.5
Peripheral neuropathy 129 20 15.5 155 19 12.3 200 31 15.5 484 70 14.5
Asthenia 141 28 19.9 178 25 14.0 232 33 14.2 551 86 15.6
Nausea and vomiting 143 47 32.9 159 30 18.9 179 41 22.9 481 118 24.5
Diarrhea 162 9 5.6 199 7 3.5 267 16 6.0 628 32 5.1
Fluid retention 160 9 5.6 196 12 6.1 257 16 6.2 613 37 6.0
Myalgia/arthralgia 133 14 10.5 159 20 12.6 230 17 7.4 522 51 9.8
Alopecia 171 0 0 209 3 1.4 280 5 1.8 660 8 1.2
aData are from the Optum Research Database, January 1, 2005 to September 30, 2012
bFollow-up time was calculated from index date until disenrollment from the health plan, death (or treatment discontinuation), or the end of the study period
(September 30, 2012)
cTotal n refers to the total number of patients without baseline events for its respective subgroup
Table 3 Treatment patterns of nab-paclitaxel initiators by line of therapya
Variable First line (n = 172) Second line (n = 211) Third or later line
(n = 281)
All (N = 664)
n % n % n % n %
Treatment regimen
Monotherapy 109 63.4 129 61.1 167 59.4 405 61.0
Combination chemotherapy 63 36.6 82 38.9 114 40.6 259 39.0
Bevacizumab 51 81.0 53 64.6 45 39.5 149 57.5




irinotecan, vinorelbine, or 5-fluorouracil
3 4.8 8 9.8 14 12.3 25 9.7
≥ 2 agents from above list 6 9.5 7 8.5 10 8.8 23 8.9
Treatment scheduleb 152 193 260 605
Weekly 114 75.0 134 69.4 180 69.2 428 70.7
q3w 38 25.0 59 30.6 80 30.8 177 29.3
Median IQR Median IQR Median IQR Median IQR
Duration of line treatment, d 159.0 (83.0–241.0) 119.0 (65.0–191.0) 122.0 (76.0–191.0) 128.0 (76.0–199.0)
Initial dose, unitc 200.0 (200.0–429.0) 200.0 (200.0–400.0) 200.0 (200.0–400.0) 200.0 (200.0–400.0)
Average dose, unitc 227.5 (200.0–394.4) 220.0 (200.0–400.0) 214.9 (200.0–400.0) 218.5 (200.0–400.0)
IQR interquartile range, q3w every 3 weeks
aData are from the Optum Research Database, January 1, 2005 to September 30, 2012
b59 patients (20 in first-line, 18 in second-line, and 21 in third-line or later therapy) could not be classified into a weekly or q3w treatment schedule
cEach unit is equivalent to 1 mg. The dosage calculated may not reflect the exact dose dispensed or received
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OS was 22.2 to 33.8 months for weekly and 27.7 months
for q3w nab-paclitaxel [13]. The OS claims for first-line
therapy (monotherapy: median of 20.8 months; weekly
median of 21.6 months) are similar to the median OS
values reported in the phase two trial for the nab-pacli-
taxel 100 mg/m2 weekly arm (22.2 months). Notably,
treatment duration with nab-paclitaxel was much longer
in the phase two trial (6.9 months), which may account
for the longer OS results vs this claims analysis.
For the patients who received nab-paclitaxel monother-
apy, the median TNTD was 5.8 months, similar to the
reported median time to disease progression of patients
with MBC who received nab-paclitaxel monotherapy
(260–300 mg/m2 q3w) for ≥ first-line treatment in the
Fig. 2 Overall survival by line of therapy. Kaplan-Meier plot depicting the cumulative probability of overall survival by line of therapy
Table 5 OS and TNTD among nab-paclitaxel initiators by line of therapy and treatment regimena,b
Variable Total no. OS TNTD
Events Median, mo 95 % CI Events Median, mo 95 % CI
Overall 664 305 17.4 (16.1–19.0) 491 6.1 (5.6–6.7)
Monotherapy 405 184 16.8 (14.5–18.5) 293 5.8 (5.0–6.7)
Combination therapy 259 121 18.7 (15.9–24.0) 198 6.5 (5.8–7.8)
First line 172 68 22.7 (18.6–34.3) 127 7.1 (6.2–9.0)
Monotherapy 109 37 20.8 (16.5–39.2) 76 6.7 (5.0–7.4)
Combination therapy 63 31 23.0 (18.7–37.3) 51 8.5 (6.5–13.1)
Second line 211 99 17.4 (14.1–22.3) 151 6.6 (5.3–8.1)
Monotherapy 129 67 15.6 (12.8–21.4) 97 5.8 (4.7–7.9)
Combination therapyc 82 32 >18.7 – 54 7.3 (5.1–9.7)
Third or later line 281 138 15.1 (12.7–16.9) 213 5.3 (4.6–6.0)
Monotherapy 167 80 15.6 (11.6–17.8) 120 5.3 (4.2–6.1)
Combination therapy 114 58 14.3 (11.9–17.4) 93 5.5 (4.6–6.4)
OS overall survival, TNTD time to next therapy or death
aData are from the Optum Research Database, January 1, 2005 to September 30, 2012
bFollow-up time was calculated from index date until disenrollment from the health plan, death (or treatment discontinuation), or the end of the study period
(September 30, 2012)
cThe 95 % CI of median survival time is missing because more than half of the patients survived during the study period
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phase two and phase three trials: 6.1 and 5.3 months, re-
spectively [10, 11]. However, the median TNTD in the
claims analysis was shorter than the median PFS reported
in the phase two trial of patients receiving first-line nab-
paclitaxel monotherapy: median PFS of 11.1 months with
300 mg/m2 q3w nab-paclitaxel and 12.8 to 12.9 months
with 100 to 150 mg/m2 weekly nab-paclitaxel [12].
This analysis also supports clinical trial data indicating
that patients with poor prognostic characteristics derive
a clinical benefit from nab-paclitaxel therapy. Patients
treated with nab-paclitaxel who were aged ≤ 50 years or
had ≥ 3 metastases had outcomes comparable with those
of the overall population (median OS: 15.6 months).
These results are also similar to those from a retrospect-
ive analysis of patients from the pivotal phase three trial
who received therapy later than first line and had ≥ 3
metastases (median OS: 13.0 months) [26]. Furthermore,
in a separate retrospective analysis of patients with poor
Fig. 3 Time to next therapy or death (TNTD) by line of therapy. Kaplan-Meier plot depicting the cumulative probability of TNTD by line of therapy
Table 6 OS and TNTD among nab-paclitaxel initiators by line of therapy and treatment schedulea,b
Variable Total No. OS TNTD
Events Median, mo 95 % CI Events Median, mo 95 % CI
Overall 605c 274 18.1 (16.7–20.8) 452 6.4 (5.8–6.8)
Weekly 428 191 18.6 (16.1–21.6) 316 6.5 (5.8–7.1)
q3w 177 83 17.4 (14.0–21.7) 136 6.0 (5.0–7.1)
First line 152 60 23.0 (19.0–37.2) 115 7.1 (6.2–9.2)
Weekly 114 49 21.6 (18.0–29.3) 85 7.4 (6.2–10.5)
q3wd 38 11 >22.7 – 30 6.6 (4.5–10.5)
Second line 193 86 19.4 (14.4–22.6) 138 6.9 (5.7–8.6)
Weekly 134 55 19.8 (14.4–23.8) 94 6.9 (5.7–8.8)
q3w 59 31 17.4 (12.0–26.1) 44 6.9 (5.0–9.9)
Third or later line 260 128 15.3 (12.8–17.0) 199 5.5 (4.9–6.2)
Weekly 180 87 15.9 (12.9–18.1) 137 5.8 (4.9–6.5)
q3w 80 41 13.5 (8.9–17.4) 62 5.0 (4.0–6.4)
OS overall survival, q3w every 3 weeks, TNTD time to next therapy or death
aData are from the Optum Research Database, January 1, 2005 to September 30, 2012
bFollow-up time was calculated from index date until disenrollment from the health plan, death (or treatment discontinuation), or the end of the study period
(September 30, 2012)
c59 patients (20 in first line, 18 in second line, and 21 in third or later line) could not be classified into a weekly or every 3 weeks treatment schedule
dThe 95 % CI of median survival time is missing because more than half of the subjects survived during the study period
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prognosis, a favorable survival benefit was demon-
strated in patients with visceral dominant metastases
(OS: 15.1–32.1 months) or a short disease-free inter-
val (OS: 14.6–19.1 months) who received nab-paclitaxel
as first-line therapy [27]. Results from this claims analysis
are similar to those for the intent-to-treat population of
those trials as well (Table 1) [10, 13].
Median TNTD and OS for patients who received nab-
paclitaxel–based combination therapy were in line with
results of clinical trials of nab-paclitaxel–based combin-
ation therapy (Table 1) [14–19]. Our analysis showed
that, when used in combination, nab-paclitaxel was most
often given with bevacizumab (58 %), and bevacizumab
combination therapy was more often initiated in the first
line (81 %). It is noted that longer survival and TNTD
were observed in the first line for combination therapy
vs monotherapy (23.0 vs 20.8 months and 8.5 vs
6.7 months, respectively). In 2011, bevacizumab for the
treatment of breast cancer was revoked by the US Food
and Drug Administration [28]. The effect of this was
reflected in a marked decrease (nearly 70 %) in the rate
of nab-paclitaxel combination therapy use after 2011
and was likely due to bevacizumab being revoked (data
not shown). At this time it is unclear what the optimal
combination partner is for nab-paclitaxel in patients
with human epidermal growth factor receptor 2–nega-
tive MBC. Currently a phase two/three trial is under
way to determine the efficacy and safety of nab-pacli-
taxel in combination with gemcitabine or carboplatin in
patients with triple-negative MBC [29].
The common adverse events identified in the clinical
trials were also explored in this claims-based study. The
occurrence of select known nab-paclitaxel toxicities (eg,
neutropenia, peripheral neuropathy, anemia, infections,
and nausea and vomiting) ranged from 15 % to 26 % and
was lower than that noted in clinical trials (Table 1)
[10–19]. In particular, the frequency of reported neur-
opathy was relatively low (<15 %) compared with that
reported in clinical trials for nab-paclitaxel [10–12],
indicating that this adverse event may have been under-
represented in the claims database. This is likely ex-
plained in part by the more robust patient monitoring
and collection of safety data in the clinical trial setting.
In addition, claims data for analysis tend to bias toward
underreporting in comparison with prospective National
Cancer Institute Common Terminology Criteria for Ad-
verse Events documentation.
Although claims analyses are extremely valuable for the
efficient and effective examination of healthcare outcomes,
treatment patterns, and healthcare resource utilization, it
is challenging to compare our study findings with those
from clinical trials. Historical trials of nab-paclitaxel re-
cruited patients according to highly restrictive criteria, and
the patients received a specific line of nab-paclitaxel
therapy, treatment regimen, or treatment schedule during
the study period. For example, the phase two trials often
targeted first-line therapy with various doses and sched-
ules, whereas the pivotal phase three trial mixed lines of
therapy at a q3w dose/schedule (Table 1). In addition,
claims analyses are unable to estimate disease progression.
TNTD may be perceived as a weak surrogate for PFS
because a potential time lapse between disease progression
and initiation of a new line of therapy is not captured. This
in effect could overestimate a benefit of treatment. Esti-
mating an overall response rate and determining the grade
of toxicities are also not feasible using claims data.
Furthermore, because claims are collected for the
purpose of payment and not research, inherent limita-
tions in our claims analysis included the potential for
incorrect reporting of diagnosis codes, mixing patients
with early-stage breast cancer with patients with MBC,
missing information on hormone receptor status, mis-
interpreting disease-onset dates, misclassifying the line
of therapy, and inaccurately estimating actual drug
dosages and schedules. However, the application of a
well-defined algorithm, including the combination of
diagnoses, procedures, and medications, reduced the
potential for false-positive cases and the misclassifica-
tion of line of therapy.
Conclusions
nab-Paclitaxel is administered more frequently as a sin-
gle agent on a weekly schedule and as second-line or
later therapy to patients with MBC in a US healthcare
system. This analysis demonstrates the use of nab-pacli-
taxel weekly or q3w and its use for the treatment of
patients aged ≤ 50 years or with ≥ 3 metastatic sites. The
benefit observed in this US healthcare system is consist-
ent with that from previously reported clinical trials. No
new safety signals were identified. Furthermore, our ana-
lysis showed that, when used in combination, nab-pacli-
taxel was most often combined with bevacizumab in
first-line therapy. However, because the accelerated ap-
proval of bevacizumab for MBC was withdrawn due to
the lack of an OS advantage in the RIBBON-1 and
AVADO trials [28], bevacizumab is no longer used as
standard therapy in MBC. Additional nab-paclitaxel
combination partners are being evaluated in patients
with MBC, including gemcitabine or carboplatin in
patients with triple-negative MBC [29]. Identification of
an optimal nab-paclitaxel combination regimen may
provide additional options for patients with MBC.
Finally, outcomes of this real-world claims analysis are
consistent with the data demonstrated in key clinical
trials, affirming the effectiveness and manageable safety
profile of nab-paclitaxel across all lines of therapy in
patients with MBC.
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